laquinimod Articles
As global MS pipelines revealed, Gilenya maintains strongest appeal, says Nomura analyst
24 October 2011
Laquinimod’s modest efficacy means it is no threat to Novartis’ Gilenya in MS, says Nomura
2 August 2011
Mixed Phase III results for Teva’s MS drug laquinimod
2 August 2011
Teva enthusiastic about oral laquinimod for multiple sclerosis on strong Ph III results
14 April 2011
Teva progresses oral multiple sclerosis ambitions with positive Ph III results for laquinimod
10 December 2010
Novartis gets Russian approval for oral MS drug Gilenya (fimgolimid)
13 September 2010
Showing 1-6 of 6 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
